Wang Lin, Ding Shaowei, Hu Yuxin, Su Jiaming, Zhu Gegongming, Hong Hanzhang, Hou Baoluo, Dong Zhaoxi, Xue Zeyu, Wang Jiayi, Liu Zhongjie, Liu Hongfang, Liu Weijing
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
Renal Research Institution of Beijing University of Chinese Medicine, Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
Front Endocrinol (Lausanne). 2025 Jun 11;16:1513895. doi: 10.3389/fendo.2025.1513895. eCollection 2025.
Diabetic kidney disease (DKD) is a leading cause of kidney failure. However, its pathogenesis remains incompletely understood, hindering the development of effective treatments. In recent years, substantial evidence has indicated that abnormal programmed cell death (PCD), including apoptosis, pyroptosis, ferroptosis, and autophagy, plays a crucial role in the progression of DKD, particularly in intrinsic renal cells such as podocytes, tubular epithelial cells, and mesangial cells. Novel therapeutic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) receptor agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and relevant traditional Chinese medicines and their formulations, have demonstrated significant efficacy in improving intrinsic renal cell PCD in DKD. This review aims to provide a concise overview of the four types of PCD and their relationship with DKD, with a particular focus on highlighting the therapeutic potential of targeting PCD signaling pathways in the treatment of DKD.
糖尿病肾病（DKD）是肾衰竭的主要原因。然而，其发病机制仍未完全明确，这阻碍了有效治疗方法的开发。近年来，大量证据表明，包括细胞凋亡、焦亡、铁死亡和自噬在内的异常程序性细胞死亡（PCD）在DKD的进展中起关键作用，尤其是在足细胞、肾小管上皮细胞和系膜细胞等肾固有细胞中。新型治疗药物，如钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂、胰高血糖素样肽-1（GLP1）受体激动剂、二肽基肽酶-4（DPP4）抑制剂以及相关的中药及其制剂，已在改善DKD肾固有细胞PCD方面显示出显著疗效。本综述旨在简要概述四种类型的PCD及其与DKD的关系，特别着重于突出靶向PCD信号通路在DKD治疗中的潜在治疗价值。
